S2647
RTT - Patient experience and quality of life
ESTRO 2026
cancer radiotherapy using elongated fractionation schedules in two rare dermatologic conditions, within a prospective observational report. Material/Methods: Patient 1: A breast cancer patient with Sweet’s syndrome undergoing adjuvant radiotherapy to the chest wall and nodes. Patient 2: A breast cancer patient with EB (skin fragility with blistering from minor trauma) requiring adjuvant breast radiotherapy. Multidisciplinary care (radiation oncology, dermatology, and surgery) guided both treatments. Radiotherapy plans were modified and proactive skin care strategies applied to minimise injury. Clinical data were collected prospectively using case report forms, medical photography at baseline (Fig. 1) and 6 weeks post-treatment (Fig. 2), and structured patient experience questionnaires. Institutional governance approval was obtained, and patients gave informed
consent. Results:
In patient 1: a typical mild erythematous reaction occurred at fraction 10 (RTOG-1). This patient completed a full 50Gy in 25-fraction treatment with FP_IMRT (6Mv) and daily CBCT verification with good tolerance, no flares, and remains free of recurrence at follow-up. Weekly blood tests for reactive protein were taken throughout treatment and remained within normal limits, supporting the absence of systemic inflammatory flare.In patient 2: despite lifelong EB with extreme skin fragility, the patient tolerated 40Gy in 15 fractions treated with FP_IMRT (6Mv) verified with daily CBCT verification. Acute toxicity was limited to mild erythema (RTOG-1) with small, isolated blistering; skin reactions were managed with water- based moisturiser and healed normally. Sequential photographs (Fig. 1–2) demonstrated the progression and resolution of skin effects. Patient experience questionnaires highlighted the value of clear communication, reassurance, and practical skin-care advice; both patients reported high satisfaction with personalised care and described treatment as less burdensome than initially feared.
Conclusion: These cases confirm that rare dermatologic conditions need not preclude curative breast cancer radiotherapy when managed through individualised, multidisciplinary approaches. Ongoing follow-up (3, 6, 12 months) will inform long-term safety and quality-of- life outcomes. Our findings build on previous reports of Sweet’s syndrome ¹ and epidermolysis bullosa ² , uniquely contributing photographic documentation and patient-reported experiences. This strengthens the limited evidence base and highlights the value of multidisciplinary, patient-centred care in complex cases. References: Ollivier L, Renaud E, Gouders D, et al. Sweet’s syndrome induced by radiations during breast cancer treatment. BMJ Case Rep. 2019;12(6):e223938.Koulis
Made with FlippingBook - Share PDF online